Review ArticleHeparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban: Clinical Case Report and Review of Current ExperiencesSamoš, Matej MD, PhD*,†; Bolek, Tomáš MD*; Ivanková, Jela DSc‡; Stančiaková, Lucia MD‡; Kovář, František MD, PhD*; Galajda, Peter MD, PhD*; Kubisz, Peter MD, DSc‡; Staško, Ján MD, PhD‡; Mokáň, Marián MD, DSc, FRCP Edin* Author Information *Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic; †Division of Molecular Medicine, BioMed Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republic; and ‡Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, National Center of Hemostasis and Thrombosis, Comenius University in Bratislava, Martin, Slovak Republic. Reprints: Matej Samoš, MD, PhD, Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, Slovak Republic (e-mail: [email protected]). The authors report no conflicts of interest. Journal of Cardiovascular Pharmacology: November 2016 - Volume 68 - Issue 5 - p 391-394 doi: 10.1097/FJC.0000000000000421 Buy Metrics Abstract Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.